These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 8951220)
1. Successful treatment of diabetes in NOD mice with advanced disease by islet isografts following immunoregulation with Linomide (quinoline-3-carboxamide). Slavin S; Weiss L; Xia W; Gross DJ Cell Transplant; 1996; 5(6):627-30. PubMed ID: 8951220 [TBL] [Abstract][Full Text] [Related]
2. Amelioration of diabetes in nonobese diabetic mice with advanced disease by linomide-induced immunoregulation combined with Reg protein treatment. Gross DJ; Weiss L; Reibstein I; van den Brand J; Okamoto H; Clark A; Slavin S Endocrinology; 1998 May; 139(5):2369-74. PubMed ID: 9564847 [TBL] [Abstract][Full Text] [Related]
3. Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug. Gross DJ; Sidi H; Weiss L; Kalland T; Rosenmann E; Slavin S Diabetologia; 1994 Dec; 37(12):1195-201. PubMed ID: 7895948 [TBL] [Abstract][Full Text] [Related]
4. Prevention and treatment of type I diabetes in NOD mice by linomide. Slavin S; Gross D; Weiss L Transplant Proc; 1995 Dec; 27(6):3240. PubMed ID: 8539933 [No Abstract] [Full Text] [Related]
5. The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus. Gross DJ; Weiss L; Reibstein I; Hedlund G; Dahlén E; Rapoport MJ; Slavin S Int Immunopharmacol; 2001 Jun; 1(6):1131-9. PubMed ID: 11407307 [TBL] [Abstract][Full Text] [Related]
6. Prevention of autoimmune diabetes by linomide in nonobese diabetic (NOD) mice is associated with up-regulation of the TCR-mediated activation of p21(ras). Rapoport MJ; Weiss L; Mor A; Bistritzer T; Ramot Y; Slavin S J Immunol; 1996 Nov; 157(10):4721-5. PubMed ID: 8906854 [TBL] [Abstract][Full Text] [Related]
8. Linomide does not prevent spontaneous autoimmune thyroiditis in NOD mice. Hartoft-Nielsen ML; Rasmussen AK; Kaas A; Bock T; Buschard K; Feldt-Rasmussen U Autoimmunity; 2001; 33(2):79-84. PubMed ID: 11264786 [TBL] [Abstract][Full Text] [Related]
9. Linomide inhibits insulitis and modulates cytokine production in pancreatic islets in the nonobese diabetic mouse. Dahlén E; Dawe K; Ohlsson L; Hall H; Hedse K; Annersten K; Aström M; Gross DJ; Hedlund G Int Immunopharmacol; 2003 Jan; 3(1):17-30. PubMed ID: 12538031 [TBL] [Abstract][Full Text] [Related]
10. Cytokine production in Linomide-treated nod mice and the potential role of a Th (1)/Th(2) shift on autoimmune and anti-inflammatory processes. Weiss L; Barak V; Zeira M; Abdul-Hai A; Raibstein I; Reich S; Hirschfeld E; Gross D; Slavin S Cytokine; 2002 Jul; 19(2):85-93. PubMed ID: 12182843 [TBL] [Abstract][Full Text] [Related]
11. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Coutant R; Landais P; Rosilio M; Johnsen C; Lahlou N; Chatelain P; Carel JC; Ludvigsson J; Boitard C; Bougnères PF Diabetologia; 1998 Sep; 41(9):1040-6. PubMed ID: 9754822 [TBL] [Abstract][Full Text] [Related]
12. Linomide increases plasma corticosterone in normal rats, but does not prevent the inhibitory action of IL-1 on beta-cells in vivo or ex vivo. Christensen UB; Mauricio D; Reimers JI; Andersen HU; Kalland T; Nerup J; Mandrup-Poulsen T Autoimmunity; 1996; 23(4):257-68. PubMed ID: 8915032 [TBL] [Abstract][Full Text] [Related]
13. Linomide, a new treatment for autoimmune diseases: the potential in type 1 diabetes. Slavin S; Sidi H; Weiss L; Rosenman E; Kalland T; Gross D Diabetes Metab Rev; 1993 Dec; 9(4):311-5. PubMed ID: 7924828 [No Abstract] [Full Text] [Related]
14. Effect of STZ administration on islet isograft and allograft survival in NOD mice. Takayama Y; Ichikawa T; Maki T Diabetes; 1993 Feb; 42(2):324-9. PubMed ID: 8425668 [TBL] [Abstract][Full Text] [Related]
15. More stringent conditions of plasmid DNA vaccination are required to protect grafted versus endogenous islets in nonobese diabetic mice. Seifarth C; Pop S; Liu B; Wong CP; Tisch R J Immunol; 2003 Jul; 171(1):469-76. PubMed ID: 12817032 [TBL] [Abstract][Full Text] [Related]
16. Effect of Linomide on adhesion molecules, TNF-alpha, nitrogen oxide, and cell adhesion. Abdul-Hai A; Hershkoviz R; Weiss L; Lider O; Slavin S Int Immunopharmacol; 2005 Feb; 5(2):231-9. PubMed ID: 15652754 [TBL] [Abstract][Full Text] [Related]
17. The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo. Borgström P; Torres Filho IP; Vajkoczy P; Strandgården K; Polaçek J; Hartley-Asp B Cancer Chemother Pharmacol; 1994; 34(4):280-6. PubMed ID: 7518359 [TBL] [Abstract][Full Text] [Related]
18. Protection of NOD islet isograft from autoimmune destruction by agarose microencapsulation. Kobayashi T; Aomatsu Y; Kanehiro H; Hisanaga M; Nakajima Y Transplant Proc; 2003 Feb; 35(1):484-5. PubMed ID: 12591496 [No Abstract] [Full Text] [Related]
19. Interleukin-4 or interleukin-10 expressed from adenovirus-transduced syngeneic islet grafts fails to prevent beta cell destruction in diabetic NOD mice. Smith DK; Korbutt GS; Suarez-Pinzon WL; Kao D; Rajotte RV; Elliott JF Transplantation; 1997 Oct; 64(7):1040-9. PubMed ID: 9381527 [TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Karussis DM; Lehmann D; Slavin S; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Kalland T; Abramsky O Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6400-4. PubMed ID: 8341645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]